피브레이트 계열 약물 : 시장 점유율 분석, 업계 동향 및 통계, 성장 예측(2026-2031년)

According to Mordor Intelligence, the fibrate drugs market size was valued at USD 3.77 billion in 2025 and estimated to grow from USD 3.97 billion in 2026 to reach USD 5.11 billion by 2031, at a CAGR of 5.19% during the forecast period (2026-2031).

This report is Segmented by Drug (Clofibrate, Gemfibrozil, Fenofibrate, Bezafibrate, Ciprofibrate, and More), Product Type (Branded and Generics), Distribution Channel (Hospital Pharmacy and Retail Pharmacy, and Online Pharmacy), and Geography (North America, Europe, Asia-Pacific, The Middle East and Africa, and South America). The Market Forecasts are Provided in Terms of Value (USD).

Global Fibrate Drugs Market Trends and Insights

Increasing Prevalence of Cardiovascular Diseases

Cardiovascular morbidity is climbing worldwide, pushing continuous demand for triglyceride-lowering agents. Chinese adults under 40 exhibited a 2.26-fold higher cardiovascular risk in the top triglyceride quartile, underscoring the contribution of elevated TG to early-age events. The American Heart Association's 2024 update projects sustained expansion of diabetes and hypertension, enlarging the clinical pool for fibrate prescriptions. Hypertriglyceridemia-induced acute pancreatitis already causes one-fifth of global cases, with the burden highest in Asia. Together, these patterns keep the fibrate drugs market firmly positioned within standard lipid-management algorithms.

High Investment in R&D of Lipid-Lowering Drugs

Capital inflows into lipid science spur innovation that often complements fibrate therapy. Breakthrough RNA therapeutics plozasiran and olezarsen lowered triglycerides far beyond conventional benchmarks in 2024 ACC presentations. Separately, Croda's USD 133 million project to expand lipid-systems capacity-bolstered by USD 75 million in U.S. federal backing-signals supply-chain confidence in lipid-based technologies. Such investment nurtures combination-product pipelines pairing fibrates with statins or novel biologics.

Payer Preference for Statins & PCSK9 Inhibitors

Reimbursement bodies prioritise statins and, increasingly, PCSK9 inhibitors, relegating fibrates to second line unless severe hypertriglyceridemia persists. Claims data reveal 30.95% PCSK9 prescriptions were denied despite price cuts, exposing formulary pressure. Cost-effectiveness models for inclisiran call for an 88% price haircut in China before parity with statin therapy frontiersin.org. Such dynamics reduce fibrate volume where payers enforce step-therapy protocols.

Other drivers and restraints analyzed in the detailed report include:

1. Rising Incidence of Metabolic Syndrome & Hypertriglyceridemia
2. Expanding Generic Manufacturing Capacity in Emerging Markets
3. Environmental Curbs on Fluorinated Intermediates Supply Chain

For complete list of drivers and restraints, kindly check the Table Of Contents.

Segment Analysis

The fibrate drugs market remains led by fenofibrate, which captured 61.90% of global revenue in 2025, a level equal to the largest fibrate drugs market share across any therapeutic class. This anchor position reflects broad clinical familiarity, once-daily dosing, and robust evidence for triglyceride lowering. Growth now centres on repurposing; LENS data show a 27% decline in diabetic-retinopathy progression, enlarging the addressable base within ophthalmology. Bezafibrate, meanwhile, enjoys the quickest uptake, advancing at a 7.12% CAGR as clinicians value its balanced safety-efficacy profile, especially in metabolic-syndrome cohorts. Gemfibrozil retains a niche role where statin interactions are mitigated, while ciprofibrate and clofibrate shrink in volume following legacy safety concerns.

Continued investment in real-world safety monitoring shapes competitive positioning. FDA adverse-event surveillance flagged 68 signals for rosuvastatin-fenofibrate combinations, 28 of which are absent from current labels, underscoring vigilance needs. That scrutiny benefits bezafibrate's reputation for lower myopathy risk. RNA-based antagonists, though not yet direct fibrate replacements, spotlight the triglyceride pathway's clinical weight, keeping the fibrate drugs market essential within multimodal lipid control regimens.

Complete Report Scope:

• By Drug
  • Clofibrate
  • Gemfibrozil
  • Fenofibrate
  • Bezafibrate
  • Ciprofibrate
  • Other Drugs
• By Product Type
  • Branded
  • Generic
• By Distribution Channel
  • Hospital & Retail Pharmacy
  • Online Pharmacy
• Geography
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Rest of Asia-Pacific
  • Middle East and Africa
    • GCC
    • South Africa
    • Rest of Middle East and Africa
  • South America
    • Brazil
    • Argentina
    • Rest of South America

Geography Analysis

North America generated 38.20% of 2025 global revenue, anchored by comprehensive reimbursement and clinical guidelines that endorse fibrates for persistent hypertriglyceridemia. Wider access to combination pills further elevates prescribing. Yet, PCSK9 coverage denials affecting nearly one-third of claims expose gaps that fibrates cost-effectively fill. Environmental restrictions raise compliance costs for U.S. producers, but established quality systems mitigate severe disruption. Canada's public-drug programs and Mexico's growing private insurance segments both widen access, sustaining regional sales momentum.

Asia-Pacific records the fastest 8.76% CAGR, driven by sizable untreated populations, rising obesity rates, and state incentives for metabolic-drug makers. India's Production Linked Incentive scheme aims at 2026 roll-out, brightening export prospects and enhancing fibrate drugs market size for regional producers. China's Strategic National Drug negotiations push price ceilings downward, preserving high volume uptake. Japan and South Korea emphasise triglyceride-specific indices, promoting earlier specialist referral. Australia leverages parallel-import policy to keep formularies cost-competitive, widening patient access.

Europe maintains a balanced outlook with payer scrutiny capping unit pricing but real-world evidence rewarding drugs that show additive cardiovascular benefit. Central and Eastern member states adopt generics aggressively, while Western Europe leans on branded innovations backed by head-to-head data. In the Middle East and Africa, economic diversification plans are raising healthcare budgets, yet uptake remains modest relative to disease prevalence. South America's macroeconomic fluctuations hobble consistent procurement, though Brazil's cardiac risk-screening expansions support gradual growth. Collectively, these patterns distribute the fibrate drugs market across a broad economic spectrum, insulating revenue from single-region shocks.

1. Abbott Laboratories
2. Abbvie
3. Ajanta Pharma USA
4. Amneal Pharmaceuticals
5. Aurobindo Pharma
6. Cipla
7. Dr. Reddy's Laboratories
8. Hikma Pharmaceuticals
9. IOL Chemicals & Pharmaceuticals
10. Kowa Pharmaceutical Co.
11. Lupin
12. Macleods Pharmaceuticals
13. Merck
14. Viatris
15. Novartis
16. Pfizer
17. Sanofi
18. Sun Pharmaceuticals Industries
19. Teva Pharmaceutical Industries
20. Unnati Pharmaceuticals

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

TABLE OF CONTENTS

1 Introduction

• 1.1 Study Assumptions & Market Definition
• 1.2 Scope of the Study

2 Research Methodology

3 Executive Summary

4 Market Landscape

• 4.1 Market Overview
• 4.2 Market Drivers
  • 4.2.1 Increasing Prevalence Of Cardiovascular Diseases
  • 4.2.2 High Investment In R&D Of Lipid-Lowering Drugs
  • 4.2.3 Rising Incidence Of Metabolic Syndrome & Hypertriglyceridemia
  • 4.2.4 Expanding Generic Manufacturing Capacity In Emerging Markets
  • 4.2.5 Therapeutic Repurposing For Diabetic Retinopathy & CKD
  • 4.2.6 Precision-Medicine Tools Enabling Targeted Fibrate Therapy
• 4.3 Market Restraints
  • 4.3.1 Frequent Product Recalls & Discontinuations
  • 4.3.2 Stringent Regulatory Framework
  • 4.3.3 Payer Preference For Statins & PCSK9 Inhibitors
  • 4.3.4 Environmental Curbs On Fluorinated Intermediates Supply Chain
• 4.4 Porter's Five Forces Analysis
  • 4.4.1 Threat of New Entrants
  • 4.4.2 Bargaining Power of Buyers
  • 4.4.3 Bargaining Power of Suppliers
  • 4.4.4 Threat of Substitutes
  • 4.4.5 Intensity of Competitive Rivalry

5 Market Size & Growth Forecasts (Value, USD)

• 5.1 By Drug
  • 5.1.1 Clofibrate
  • 5.1.2 Gemfibrozil
  • 5.1.3 Fenofibrate
  • 5.1.4 Bezafibrate
  • 5.1.5 Ciprofibrate
  • 5.1.6 Other Drugs
• 5.2 By Product Type
  • 5.2.1 Branded
  • 5.2.2 Generic
• 5.3 By Distribution Channel
  • 5.3.1 Hospital & Retail Pharmacy
  • 5.3.2 Online Pharmacy
• 5.4 Geography
  • 5.4.1 North America
    • 5.4.1.1 United States
    • 5.4.1.2 Canada
    • 5.4.1.3 Mexico
  • 5.4.2 Europe
    • 5.4.2.1 Germany
    • 5.4.2.2 United Kingdom
    • 5.4.2.3 France
    • 5.4.2.4 Italy
    • 5.4.2.5 Spain
    • 5.4.2.6 Rest of Europe
  • 5.4.3 Asia-Pacific
    • 5.4.3.1 China
    • 5.4.3.2 Japan
    • 5.4.3.3 India
    • 5.4.3.4 South Korea
    • 5.4.3.5 Australia
    • 5.4.3.6 Rest of Asia-Pacific
  • 5.4.4 Middle East and Africa
    • 5.4.4.1 GCC
    • 5.4.4.2 South Africa
    • 5.4.4.3 Rest of Middle East and Africa
  • 5.4.5 South America
    • 5.4.5.1 Brazil
    • 5.4.5.2 Argentina
    • 5.4.5.3 Rest of South America

6 Competitive Landscape

• 6.1 Market Concentration
• 6.2 Market Share Analysis
• 6.3 Company Profiles (includes Global level Overview, Market level overview, Core Segments, Financials as available, Strategic Information, Market Rank/Share for key companies, Products & Services, and Recent Developments)
  • 6.3.1 Abbott Laboratories
  • 6.3.2 AbbVie Inc
  • 6.3.3 Ajanta Pharma USA
  • 6.3.4 Amneal Pharmaceuticals
  • 6.3.5 Aurobindo Pharma USA
  • 6.3.6 Cipla Ltd
  • 6.3.7 Dr. Reddy's Laboratories
  • 6.3.8 Hikma Pharmaceuticals
  • 6.3.9 IOL Chemicals & Pharmaceuticals
  • 6.3.10 Kowa Pharmaceutical Co.
  • 6.3.11 Lupin Ltd
  • 6.3.12 Macleods Pharmaceuticals
  • 6.3.13 Merck & Co.
  • 6.3.14 Viatris Inc
  • 6.3.15 Novartis AG
  • 6.3.16 Pfizer Inc
  • 6.3.17 Sanofi S.A
  • 6.3.18 Sun Pharmaceutical Industries
  • 6.3.19 Teva Pharmaceutical Industries
  • 6.3.20 Unnati Pharmaceuticals

7 Market Opportunities & Future Outlook

• 7.1 White-space & Unmet-need Assessment